nach oben

Drugs & Aging

Erschienen in:

01.01.2008 | Therapy In Practice

Sjögren’s Syndrome

Diagnosis and Therapeutic Challenges in the Elderly

verfasst von: Kristine P. Ng, Professor David A. Isenberg

Erschienen in: Drugs & Aging | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Sjögren’s syndrome (SS) is a chronic autoimmune rheumatic disease characterized by keratoconjunctivitis sicca and xerostomia as a result of lymphocytic infiltration of the lacrimal and salivary glands. Extra-glandular manifestations occur in about one-third of patients with SS. The diagnosis of SS in the geriatric population is not straightforward and consideration needs to be given to exclusion of other conditions that may have similar presenting symptoms. The presence of autoantibodies, in particular anti-Ro and anti-La antibodies, may aid in the diagnosis of SS. Salivary gland biopsy findings represent one of the objective criteria included in the widely accepted American-European classification diagnostic criteria. However, SS-like histological changes can also be present in the healthy elderly, adding to the dilemma in diagnosing this condition in the geriatric population. Management of SS involves local treatment of dry eyes and mouth with replacement and stimulation therapies. Patients with more serious systemic involvement may require immunosuppressive therapy. Medications that are routinely used in the treatment of patients with SS often have limited use in the elderly population because patients in the latter group may have complex comorbid conditions and be taking multiple medications. Recently, use of newer targeted therapies has been explored in SS. This article provides an update on recent developments in the diagnosis and management of SS, with emphasis on issues that may arise when treating elderly patients with this condition.

The use of trade names is for product identification purposes only and does not imply endorsement.

Manthorpe R, Asmussen K, Oxholm P. Primary Sjogren’s syndrome: diagnostic criteria, clinical features and disease activity. J Rheumatol Suppl 1997 Sep; 50: 8–11PubMed

Sanchez-Guerrero J, Perez-Dosal MR, Cardenas-Velazquez F, et al. Prevalence of Sjogren’s syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology (Oxford) 2005 Feb; 44(2): 235–40CrossRef

Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjogren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 2006 Feb; 45(2): 187–91CrossRef

Drosos AA, Andonopoulos AP, Costopoulos JS, et al. Prevalence of primary Sjogren’s syndrome in an elderly population. Br J Rheumatol 1988 Apr; 27(2): 123–7PubMedCrossRef

Whaley K, Williamson J, Wilson T, et al. Sjogren’s syndrome and autoimmunity in a geriatric population. Age Ageing 1972 Nov; 1: 197–206PubMedCrossRef

Tapinos NI, Polihronis M, Tzioufas AG, et al. Sjogren’s syndrome: autoimmune epithelitis. Adv Exp Med Biol 1999; 455: 127–34PubMedCrossRef

McArthur C, Wang Y, Veno P, et al. Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha. Arch Oral Biol 2002 Jun; 47(6): 443–8PubMedCrossRef

Venables PJ, Rugby SP. Viruses in the etiopathogenesis of Sjogren’s syndrome. J Rheumatol Suppl 1997 Sep; 50: 3–5PubMed

Sawalha AH, Potts R, Schmid WR, et al. The genetics of primary Sjogren’s syndrome. Curr Rheumatol Rep 2003 Aug; 5(4): 324–32PubMedCrossRef

10.

Manthorpe R, Oxholm P, Prause JU, et al. The Copenhagen criteria for Sjogren’s syndrome. Scand J Rheumatol Suppl 1986; 61: 19–21PubMed

11.

Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren’s syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993 Mar; 36(3): 340–7PubMedCrossRef

12.

Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 Jun; 61(6): 554–8PubMedCrossRef

13.

Price EJ, Venables PJ. Dry eyes and mouth syndrome: a subgroup of patients presenting with sicca symptoms. Rheumatology (Oxford) 2002 Apr; 41(4): 416–22CrossRef

14.

Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999 Jun 28; 159(12): 1359–63PubMedCrossRef

15.

Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. Salisbury Eye Evaluation. J Rheumatol 1998 Mar; 25(3): 486–91PubMed

16.

Hermann GA, Vivino FB, Goin JE. Scintigraphic features of chronic sialadenitis and Sjogren’s syndrome: a comparison. Nucl Med Commun 1999 Dec; 20(12): 1123–32PubMedCrossRef

17.

Kalk WW, Vissink A, Spijkervet FK, et al. Morbidity from parotid sialography. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 Nov; 92(5): 572–5PubMedCrossRef

18.

Kalk WW, Vissink A, Spijkervet FK, et al. Parotid sialography for diagnosing Sjogren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002 Jul; 94(1): 131–7PubMedCrossRef

19.

Radfar L, Kleiner DE, Fox PC, et al. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 2002 Oct 15; 47(5): 520–4PubMedCrossRef

20.

Xu KP, Katagiri S, Takeuchi T, et al. Biopsy of labial salivary glands and lacrimal glands in the diagnosis of Sjogren’s syndrome. J Rheumatol 1996 Jan; 23(1): 76–82PubMed

21.

de Wilde PC, Baak JP, Slootweg PJ, et al. Morphometry in the diagnosis of Sjogren’s syndrome. Anal Quant Cytol Histol 1986 Mar; 8(1): 49–55PubMed

22.

Pennec YL, Leroy JP, Jouquan J, et al. Comparison of labial and sublingual salivary gland biopsies in the diagnosis of Sjogren’s syndrome. Ann Rheum Dis 1990 Jan; 49(1): 37–9PubMedCrossRef

23.

Fox PC. Simplified biopsy technique for labial minor salivary glands. Plast Reconstr Surg 1985 Apr; 75(4): 592–3PubMedCrossRef

24.

Daniels TE. Labial salivary gland biopsy in Sjogren’s syndrome: assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984 Feb; 27(2): 147–56PubMedCrossRef

25.

Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjogren’s disease. J Clin Pathol 1968 Sep; 21(5): 656–60PubMedCrossRef

26.

Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: analysis of 618 patients with suspected Sjogren’s syndrome. Arthritis Rheum 1994 Jun; 37(6): 869–77PubMedCrossRef

27.

Greenspan JS, Daniels TE, Talal N, et al. The histopathology of Sjogren’s syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol 1974 Feb; 37(2): 217–29PubMedCrossRef

28.

Kikuchi M, Inagaki T, Ogawa K, et al. Histopathological investigation of salivary glands in the asymptomatic elderly. Arch Gerontol Geriatr 2004 Mar–Apr; 38(2): 131–8PubMedCrossRef

29.

Larsson A, Bredberg A, Henriksson G, et al. Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjogren’s syndrome and healthy subjects. Scand J Immunol 2005 Jan; 61(1): 98–107PubMedCrossRef

30.

Adamson 3rd TC, Fox RI, Frisman DM, et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies. J Immunol 1983 Jan; 130(1): 203–8PubMed

31.

Manthorpe R, Benoni C, Jacobsson L, et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients: can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjogren’s syndrome? Ann Rheum Dis 2000 Jan; 59(1): 54–60PubMedCrossRef

32.

Morimoto Y, Habu M, Tomoyose T, et al. Dynamic magnetic resonance sialography as a new diagnostic technique for patients with Sjogren’s syndrome. Oral Dis 2006 Jul; 12(4): 408–14PubMedCrossRef

33.

Hocevar A, Ambrozic A, Rozman B, et al. Ultrasonographic changes of major salivary glands in primary Sjogren’s syndrome: diagnostic value of a novel scoring system. Rheumatology 2005 Jun; 44(6): 768–72PubMedCrossRef

34.

Niemela RK, Takalo R, Paakko E, et al. Ultrasonography of salivary glands in primary Sjogren’s syndrome: a comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. Rheumatology 2004 Jul; 43(7): 875–9PubMedCrossRef

35.

Manoussakis MN, Tzioufas AG, Silis MP, et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987 Sep; 69(3): 557–65PubMed

36.

Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjogren’s syndrome. Scand J Rheumatol 1999; 28(4): 227–32PubMedCrossRef

37.

Tishler M, Yaron I, Shirazi I, et al. Clinical and immunological characteristics of elderly onset Sjogren’s syndrome: a comparison with younger onset disease. J Rheumatol 2001 Apr; 28(4): 795–7PubMed

38.

Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjogren’s syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8(1): 20–3PubMedCrossRef

39.

Asmussen K, Andersen V, Bendicen G, et al. A new model for classification of disease manifestations in primary Sjogren’s syndrome: evaluation in a retrospective long term study. J Int Med 1996 Jun; 239(6): 475–82CrossRef

40.

Daniels TE, Silverman Jr S, Michalski JP, et al. The oral component of Sjogren’s syndrome. Oral Surg 1975 Jun; 39(6): 875–85PubMedCrossRef

41.

Fox RI. Clinical features, pathogenesis, and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 1996 Sep; 8(5): 438–45PubMedCrossRef

42.

Freeman SR, Sheehan PZ, Thorpe MA, et al. Ear, nose, and throat manifestations of Sjogren’s syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol 2005 Feb; 34(1): 20–4PubMedCrossRef

43.

Haga HJ, Gjesdal CG, Irgens LM, et al. Reproduction and gynaecological manifestations in women with primary Sjogren’s syndrome: a case-control study. Scand J Rheumatol 2005; 34(1): 45–8PubMedCrossRef

44.

Wright SA, Convery RP, Liggett N. Pulmonary involvement in Sjogren’s syndrome. Rheumatology (Oxford) 2003 May; 42: 697–8CrossRef

45.

Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006 Nov; 130(5): 1489–95PubMedCrossRef

46.

Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjogren’s syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999 Jan; 58(1): 61–4PubMedCrossRef

47.

Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjogren’s syndrome. Ann Rheum Dis 2000 Sep; 59(9): 709–12PubMedCrossRef

48.

Soy M, Piskin S. Cutaneous findings in patients with primary Sjogren’s syndrome. Clin Rheumatol 2006; 26(8): 1350–2PubMedCrossRef

49.

Bernacchi E, Amato L, Parodi A, et al. Sjogren’s syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol 2004 Jan–Feb; 22(1): 55–62PubMed

50.

Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004 Mar; 83(2): 96–106CrossRef

51.

Pease CT, Shattles W, Barrett NK, et al. The arthropathy of Sjogren’s syndrome. Br J Rheumatol 1993 Jul; 32(7): 609–13PubMedCrossRef

52.

Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren’s syndrome. Ann Rheum Dis 2005 Jan; 64(1): 114–7PubMedCrossRef

53.

Ostuni P, Botsios C, Sfriso P, et al. Fibromyalgia in Italian patients with primary Sjogren’s syndrome. Joint Bone Spine 2002 Jan; 69(1): 51–7PubMedCrossRef

54.

Giles I, Isenberg D. Fatigue in primary Sjogren’s syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis 2000 Nov; 59(11): 875–8PubMedCrossRef

55.

Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sjogren’s syndrome and is not related to muscle pain. J Rheumatol 2002 Apr; 29(4): 717–25PubMed

56.

Binder A, Snaith ML, Isenberg D. Sjogren’s syndrome: a study of its neurological complications. Br J Rheumatol 1988 Aug; 27(4): 275–80PubMedCrossRef

57.

Govoni M, Padovan M, Rizzo N, et al. Neurological involvement in primary Sjogren’s syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001; 15(8): 597–607PubMedCrossRef

58.

Lafitte C, Amoura Z, Cacoub P, et al. Neurological complications of primary Sjogren’s syndrome. J Neurol 2001 Jul; 248(7): 577–84PubMedCrossRef

59.

Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjogren syndrome: a population-based study. Arch Neurol 2006 Nov; 63(11): 1612–5PubMedCrossRef

60.

Lopate G, Pestronk A, Al-Lozi M, et al. Peripheral neuropathy in an outpatient cohort of patients with Sjogren’s syndrome. Muscle Nerve 2006 May; 33(5): 672–6PubMedCrossRef

61.

Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, et al. Involvement of the peripheral nervous system in primary Sjogren’s syndrome. Ann Rheum Dis 2001 Sep; 60(9): 876–81PubMed

62.

Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sjogren’s syndrome: a controlled study. J Rheumatol 1998 Dec; 25(12): 2385–8PubMed

63.

Alexander EL. Neurologic disease in Sjögren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle: a clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993 Nov; 19(4): 869–908PubMed

64.

Coates T, Slavotinek JP, Rischmueller M, et al. Cerebral white matter lesions in primary Sjogren’s syndrome: a controlled study. J Rheumatol 1999 Jun; 26(6): 1301–5PubMed

65.

de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001 Jan; 70(1): 9–14PubMedCrossRef

66.

Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjogren’s syndrome. Nephrol Dial Transplant 2001 Dec; 16(12): 2328–36PubMedCrossRef

67.

Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore) 2000 Jul; 79(4): 241–9CrossRef

68.

Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitislike urinary symptoms among patients with Sjogren’s syndrome: a population-based study in Finland. Am J Med 2003 Jul; 115(1): 62–5PubMedCrossRef

69.

Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993 Sep 4; 342(8871): 575–7PubMedCrossRef

70.

Raderer M, Osterreicher C, Machold K, et al. Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 2001 Jul; 12(7): 937–9PubMedCrossRef

71.

Kaplan MJ, Ike RW. The liver is a common non-exocrine target in primary Sjogren’s syndrome: a retrospective review. BMC Gastroenterol 2002 Sep 13; 2: 21PubMedCrossRef

72.

Miller EB, Shichmanter R, Friedman JA, et al. Granulomatous hepatitis and Sjogren’s syndrome: an association. Semin Arthritis Rheum 2006 Dec; 36(3): 153–8PubMedCrossRef

73.

Reichlin M. Antibodies to Ro and La. Ann Med Interne (Paris) 1998 Feb; 149(1): 34–41

74.

Ramos-Casals M, Nardi N, Brito-Zeron P, et al. Atypical auto-antibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 2006 Apr; 35(5): 312–21PubMedCrossRef

75.

Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary Sjogren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 2002 Jul; 81(4): 281–92CrossRef

76.

Stewart A, Blenkinsopp PT, Henry K. Bilateral parotid MALT lymphoma and Sjogren’s syndrome. Br J Oral Maxillofac Surg 1994 Oct; 32(5): 318–22PubMedCrossRef

77.

Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978 Dec; 89(6): 888–92PubMed

78.

Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006 Jun; 65(6): 796–803PubMedCrossRef

79.

Lazarus M, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 2006; 45: 1012–5PubMedCrossRef

80.

Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum 1999 Aug; 42(8): 1765–72PubMedCrossRef

81.

Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006 Mar; 18(2): 129–34PubMedCrossRef

82.

Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum 2002 Mar; 46(3): 741–7PubMedCrossRef

83.

Anaya JM, Tobon GJ, Vega P, et al. Autoimmune disease aggregation in families with primary Sjogren’s syndrome. J Rheum 2006 Nov; 33(11): 2227–34PubMed

84.

Lazarus M, Isenberg D. Development of additional autoimmune diseases in a population of patients with primary Sjogren’s syndrome. Ann Rheum Dis 2005 Jul; 64: 1062–4PubMedCrossRef

85.

Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999 Jan 25; 159(2): 174–81PubMedCrossRef

86.

Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren’s syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003 Dec; 62(12): 1204–7PubMedCrossRef

87.

Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002 Mar; 46(3): 748–54PubMedCrossRef

88.

Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 2002 Jun 10; 162(11): 1293–300PubMedCrossRef

89.

Cummins M, Papas A, Kammer G, et al. Treatment of primary Sjogren’s syndrome with low dose human interferon alpha administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49(4): 585–93PubMedCrossRef

90.

Fox RI, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996 Jun; 5Suppl. 1: S31–6PubMedCrossRef

91.

Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993 May; 52(5): 360–4PubMedCrossRef

92.

Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjogren’s syndrome. Clin Exp Rheumatol 1996 Sep–Oct; 14(5): 555–8PubMed

93.

Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren’s syndrome. J Rheumatol 1998 May; 25(5): 896–9PubMed

94.

Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporin A therapy in patients with primary Sjogren’s syndrome: results at one year. Scand J Rheumatol Suppl 1986; 61: 246–9PubMed

95.

Kizawa M, Mori K, Iijima M, et al. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren’s syndrome. J Neurol Neurosurg Psychiatry 2006 Aug; 77(8): 967–9PubMedCrossRef

96.

de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to Sjogren’s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol 2006 Apr; 33(4): 709–11PubMed

97.

Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore) 2004 Sep; 83(5): 280–91CrossRef

98.

Miyawaki S, Nishiyama S, Matoba K. Efficacy of low dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren’s syndrome. Intern Med 1999 Dec; 38(12): 938–43PubMedCrossRef

99.

Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004 Jul; 50(7): 2240–5PubMedCrossRef

100.

Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheum 2004 Apr; 50(4): 1270–6PubMedCrossRef

101.

Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum 2005 Sep; 52(9): 2740–50PubMedCrossRef

102.

Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8(4): R129PubMedCrossRef

103.

Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren’s syndrome patients. Eye 2005 May; 19(5): 535–9PubMedCrossRef

104.

Marsh P, Pflugfelder SC. Topical nonpreserved methyl-prednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999 Apr; 106(4): 811–6PubMedCrossRef

105.

Hong S, Kim T, Chung S, et al. Recurrence after topical non-preserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren’s syndrome. J Ocul Pharm Therapeut 2007; 23: 78–82CrossRef

106.

Sall K, Stevenson O, Mondorf T, et al. Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eyes: CsA Phase 3 Study Group. Ophthalmology 2000 Apr; 107(4): 631–9PubMedCrossRef

107.

Tatlipinar S, Akpek E. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 2005 Oct; 89(10): 1363–7PubMedCrossRef

108.

Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta Ophthalmol (Copenh) 1994 Aug; 72(4): 438–42CrossRef

109.

Al-Hashimi I. Xerostomia secondary to Sjögren’s syndrome in the elderly: recognition and management. Drugs Aging 2005; 22(11): 887–99PubMedCrossRef

110.

van der Reijden WA, van der Kwaak H, Vissink A, et al. Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjogren’s syndrome. Arthritis Rheum 1996 Jan; 39(1): 57–63PubMedCrossRef

111.

Mulherin D, Ainsworth JR, Hamburger J, et al. Survey of artificial tear and saliva usage among patients with Sjogren’s syndrome [letter]. Ann Rheum Dis 2001 Nov; 60(11): 1077PubMedCrossRef

112.

Venables PJ. Management of patients presenting with Sjogren’ syndrome. Best Pract Res Clin Rheumatol 2006 Aug; 20(4): 791–807PubMedCrossRef

113.

Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 Jan; 95(1): 38–44PubMedCrossRef

114.

Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjogren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999 Aug; 19(8): 943–51PubMedCrossRef

115.

Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren’s syndrome. J Interferon Cytokine Res 1998 Apr; 18(4): 255–62PubMedCrossRef

116.

Ferraccioli GF, Salaffi F, De Vita S, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren’s syndrome patients: preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996 Jul–Aug; 14(4): 367–71PubMed

117.

Kastrup O, Maschke M, Diener HC. Pulse-cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren’s syndrome. Clin Neurol Neurosurg 2005 Aug; 107(5): 440–1PubMedCrossRef

118.

Levy Y, Uziel Y, Zandman G, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis 2003 Dec; 62(12): 1221–3PubMedCrossRef

119.

Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren’s syndrome: a pilot study. Arthritis Rheum 2001 Oct; 44(10): 2371–5PubMedCrossRef

120.

Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006 Aug; 65(8): 1033–7PubMedCrossRef

Titel: Sjögren’s Syndrome
Diagnosis and Therapeutic Challenges in the Elderly
verfasst von: Kristine P. Ng
Professor David A. Isenberg
Publikationsdatum: 01.01.2008
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 1/2008
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200825010-00003

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Association of Potentially Inappropriate Medication Use with Adverse Outcomes in Ambulatory Elderly Patients with Chronic Diseases

Why Do We Believe that Breast Cancer in the Elderly is the Same as Breast Cancer in Young Women?

Benzodiazepines and Injurious Falls in Community Dwelling Elders

Fondaparinux

Early Breast Cancer in the Elderly